Sorrento, Samyang deal

Samyang granted Sorrento exclusive rights to develop and commercialize Cynviloq in Australia, Canada and Mexico. Sorrento already has rights to the injectable nanoparticle formulation of paclitaxel in the U.S. and EU. Last May, Samyang granted EU rights to Sorrento and Igdrasol Inc. and U.S. rights to Igdrasol. Sorrento acquired Igdrasol in September. Samyang markets the product as Genexol-PM in South Korea. The companies could not be reached for details. ...